Adocia is a clinical-stage biotechnology company specialized in the development of innovative treatments for diabetes and obesity.

Adocia

ADOCIA | 10,583 followers on LinkedIn. &quot;Innovative medicine for everyone, everywhere&quot;​ | &quot;Innovative medicine for everyone, everywhere&quot;​ 

Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. 

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

Investor, Advisor, Board Member

Mads Dall

Claire Mégret

Director of Innovation & Physico-Chemistry Department ADOCIA

Emmanuel Dauty

Head of Process Chemistry Development at ADOCIA

Guilhem Mora

ADOCIA

#ETUDE | Dépôts de brevets et innovation : focus sur la dynamique portée par les #PME françaises 🇫🇷 On recense environ 159 000 PME en France qui sont essentielles dans le paysage de l'innovation, notamment dans les technologies avancées 🚀 Le ratio pour les PME est de 1 brevet pour 3 millions d’euros investis en R&D 💶 Malgré une stagnation de leurs publications depuis 2019, 80 % des demandes de cette catégorie d’entreprise proviennent de petites PME, souvent des  #startups dynamiques. Celles âgées de 5 à 19 ans représentent la moitié des dépôts, démontrant une forte capacité d’innovation et de résilience 🛡️ Le portefeuille des brevets en vigueur des PME a augmenté de 11% depuis 2020 ↗️ 44% des demandes de brevets en technologie médicale proviennent des PME ⚕️ Ci-dessous le palmarès des 15 premières PME déposantes de brevets depuis 2019 ⤵️ En savoir plus 👉 https://bit.ly/3NYmTCg Téléchargez l'étude : 🔗 https://bit.ly/40ApHwZ Aledia | Isorg | SuperGrid Institute | IRT b-com | Petzl | IRT Jules Verne | WHYLOT | FOGALE Sensors | CPE Lyon | PKvitality | Aryballe | Tallano Technologies | IRT AESE - Saint Exupéry | NAOS Medical (Bioderma - Institut Esthederm - Etat Pur) | ADOCIA | eLichens | BIORET CORP | ITEN - Solid-state micro-batteries | Moving Magnet Technologies (MMT)

INPI France

🤝 ADOCIA is heading north for #partnering ! Join Mathieu-William Gilbert , Adocia COO-CFO, and Jeremy Benattar , Head of Marketing & Strategy, at #BIOEurope , November 4–6, 2024, in Stockholm, Sweden. The event marks 30 years of facilitating partnerships by EBD Group . It's not too late to request a meeting with them if you're interested in learning more about our latest innovations (hormonal combinations, long-acting injectables, oral delivery of peptides, cell delivery and much more!): ➡️ Request a meeting: https://lnkd.in/edKBRYf See you in Stockholm? #Biotech #LAI #OralDelivery #CellTherapy #Diabetes #Obesity

Merci Stéphanie Maugey - Brunelle pour cette belle mise en lumière ! 👍

🚀 ADOCIA is thrilled to announce its participation in the “Partnership Opportunities in Drug Delivery” (PODD) Conference! 🚀 Emmanuel Dauty , Adocia Director of #Innovation , will be showcasing our innovative technology platforms to potential partners: ♦️ #AdoGel , for sustained release of peptides is designed as a solution to reduce patient burden. Applied to #semaglutide , we achieved a release lasting over one month! ♦️ #AdoShell , a unique approach to cell delivery and is currently being applied to islets of Langerhans. ♦️ #AdOral , our solution to improve the bioavailability of peptides for oral delivery. ♦️ And of course, our historical #BioChaperone ®, designed to combine and stabilize incompatible hormones to treat obesity and diabetes, with the most recent applications to #cagrilintide and #semaglutide . 📅 Event Date: October 28-29, 2024 📍 Location: Boston, MA ➡️ For more info: https://lnkd.in/gQ_wSyBb If you're attending, be sure to connect with Emmanuel Dauty to explore our cutting-edge science and discover how our innovations could be the solution to your toughest drug delivery challenges! #PODD2024 #DrugDelivery #BioChaperone #Obesity #Diabetes #Innovation #SustainedRelease

[Press Release] 📰 Today, ADOCIA proudly announces the patenting of stable combinations of #GLP -1 and #amylin analogs for treating obesity and diabetes using our innovative #BioChaperone ® platform. Once more, the BioChaperone® platform has demonstrated its capability to "mix the unmixable", delivering a stable formulation of #semaglutide combined with #cagrilintide ("CagriSema"), hormones that are otherwise incompatible. This resulting combination could be administered through all standard subcutaneous injection devices, including multi-use, achieving one goal: to treat more patients, at constant manufacturing capacities, thereby adressing the exploding demand for obesity and diabetes products. #Biotech #Peptides #Diabetes #Obesity #Adocia #Innovation

[IR Event] Olivier Soula, CEO of ADOCIA , and Mathieu-William Gilbert , COO-CFO, will participate in the Portzamparc Groupe BNP Paribas ’ "Biotech and Health" digital seminar, on October 8 - 9, 2024. 📅 On October 9, 3:30 PM - 4:15 PM, they will have the opportunity to discuss with the investor community our latest advances and our strategic perspectives. #Investments #Investors #Biotech

🚀 ADOCIA is excited to announce our participation in #CPHI Milano 2024, from October 8th to 10th. We’re using this opportunity to meet with industry professionals, strengthen existing collaborations, and explore new prospects for our projects. 🧫 One of our focuses is securing essential components for our cell therapy program - AdoShell Islets - as we prepare for our first in-human trial, expected next year. 🏥 We look forward to productive discussions and new opportunities at CPHI Milano! Feel free to contact David Rigal , Pharmaceutical Development Director, Charles Fortier , Senior Research Scientist in Drug Product Development, or Jeremy Benattar , Head of Marketing Strategy, to schedule a meeting or simply for a chat! #CPHIMilano #AdoShellIslets #FirstInHumanTrial #Networking #Biotech

🛬 Mathieu-William Gilbert , just back from the Forum LYON POLE BOURSE , is now in Amsterdam to participate in #Pharmageddon EU 2024! After launching in 2023 by Impatient Health , Pharmageddon set out to revolutionize pharma by creating a space where creative and innovative minds can collaborate. With a commitment to action, not just discussion, this two-day event aims to deconstruct and rebuild the industry. At 5:00 p.m. CEST, he will join a dynamic panel on Proactive Health Equity, alongside industry leaders Marijn Verhoef and Olivia Kager . This panel will dive deep into the next chapter of health equity, focusing on how we can not just react but anticipate and eliminate access barriers before they arise. By leveraging insights to ensure that healthcare solutions reach everyone, this conversation aims to drive both social impact and open new commercial pathways. ➡ For more information: https://lnkd.in/eWmSAY8E #PharmageddonEU #HealthEquity #Innovation #Inclusion #HealthcareTransformation #FutureOfPharma

[Press Release] 📃 ADOCIA Announces Appointment of Mathieu-William Gilbert as Chief Financial Officer Mathieu-William Gilbert will serve as Chief Financial Officer in addition to his position as Chief Operating Officer, which he has held since May 2024. Valérie Danaguezian , who has held the position of #CFO since Adocia’s founding in 2005, is leaving the company to focus on a family project. Mathieu-William Gilbert joined the Company following a distinguished career of more than fifteen years at Novo Nordisk, where he held #VicePresident and #GeneralManager positions for several subsidiaries. In his expanded role, Mathieu-William Gilbert will oversee administrative and #financial functions, #investor relations, #legal affairs, and #HumanResources . He is also a member of the #Executive Committee and serves as #SecretaryGeneral of the Board of Directors. Mathieu-William Gilbert , welcome to the team 🙌 Valérie Danaguezian , we wish you all the success in your new endeavors!! 💟 ➡ Find out more on the full Press Release: https://lnkd.in/ecskKmq5

🚀 Demain, retrouvez ADOCIA lors du Forum LYON POLE BOURSE ! L'équipe dirigeante d'Adocia, rassemblant Olivier Soula, Valérie Danaguezian , et Mathieu-William Gilbert , se joint à cet évènement annuel incontournable pour entretenir les relations et échanger avec un réseau de plus de 120 investisseurs ! 📅 Date : mardi 24 septembre 📍 Lieu : Palais du Commerce - Place de la Bourse - 69002 Lyon Pour plus d’informations 👉 https://lnkd.in/fyiEkUS #LyonPoleBourse #Investissement #Financement #Bourse #Innovation

HSTS

DNSSEC

Mobile Non Scaleable Content

jQuery CDN

Apache 2.4

PHP 7

Smart App Banner

Sectigo SSL

Invalid Certificate Dates

OpenSSL

Chairman

Gerard Soula

Project Lead

Ouardane Jouannot

Research Scientist

Romain Noel

Research Scientist in Analytical Chemistry

Yves Meyer

Remi Droller

Katherine S. Bowdish

Olivier Soula

Co-founder, Deputy Chief Executive Officer, and Director of Research and Development

Valérie Danaguezian

Chief Financial Officer

Gérard Soula

President and CEO

Lyon Companies With More Than $1M in Revenue

Lyon Companies With More Than 10 Employees

European Union (EU) Biotechnology Companies

European Union (EU) Public Companies With Less Than $500M in Revenue

Adocia operates as a biotechnology company specializing in tissue regeneration. Adocia was founded in 2005 as Proteins & Peptides Management S.A.S. and changed its name to Adocia in January 2008. Adocia is based in Lyons, France.

Post-IPO Debt - Adocia

Series B - Adocia

Venture Round - Adocia

Lyon

Rhone-Alpes

France

Europe

Adocia: patent applications filed

Adocia Announces Appointment Of Mathieu‑William Gilbert As CFO

ADOCIA Reports Second Quarter 2024 Financial Results and Provides a Business Update

ADOCIA Announces Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets

ADOCIA Announces That Tonghua Dongbao Is Discontinuing One of the Two Partnership Programs: BioChaperone

Adocia: end of insulin partnership program

ADOCIA Announces That Tonghua Dongbao Is Discontinuing One of the Two Partnership Programs: BioChaperone® Combo

Adocia appoints Director of Operations

ADOCIA Confirms Its Eligibility for the PEA–PME

Number of Shares and Voting Rights of ADOCIA as of April 30th, 2024

A novel ultra-rapid prandial insulin formulation for more effective blood glucose management.

An ultra-rapid prandial insulin formulation for better management of blood glucose levels.

A fixed combination of long-acting insulin glargine and rapid-acting insulin lispro for type 2 diabetes treatment.

A hydrogel-based implant containing islets of Langerhans for cell therapy against type 1 diabetes.

United Kingdom

India

Asia

Denmark

HTML5

Comodo PositiveSSL Certificates

Disqus

Vimeo

Wordpress

Adobe Fonts

Google Maps API

Modernizr

Google Analytics

Google Fonts

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

news impact assignment basic	general
public peers	general	Nov 9, 2024 10:05 PM	691c9d16
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 9, 2024 10:05 PM	624d4ddf
crunchbase trigger	general	Nov 27, 2024 12:50 PM	65f1d31e
crunchbase profile	general	Nov 28, 2024 8:30 AM	d3e75e53
li profile	general	Nov 9, 2024 10:05 PM	981109fd
translate crunchbase fundingrounds	general	Nov 28, 2024 9:13 AM	23f563a0
peers	general	Nov 9, 2024 10:05 PM	ee7c2e9a
news basic	general	Nov 9, 2024 10:05 PM	c36d6536
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ADOCIA

Adocia

Last Close

8.13

25/11 09:23

Market Cap

94.95M

Beta: -

Volume Today

25.12K

Avg: -